Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Reggie Kelly"'
1
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP
Autor: Roger M. Lyons, Chien Feng Chen, James N. George, Israel Wiznitzer, Louis M. Aledort, James B. Bussel, Robert McMillan, David J. Kuter, George T. Conklin, Jorge Nieva, Alan E. Lichtin, Janet L. Nichol, Reggie Kelly, Jeffrey S. Wasser
Publikováno v: The New England journal of medicine. 355(16)
Most current treatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platelet destruction. In a phase 1-2 study, we administered a thrombopoiesis-stimulating protein, AMG 531, to patients with ITP.In phase 1, 24 patients who ha
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74d87921c22188fb05a6a307685c4007
https://pubmed.ncbi.nlm.nih.gov/17240535
Zobrazit plný text záznamu
2
Evaluation of AMG 531 Efficacy in Nonsplenectomized Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in a Randomized Placebo-Controlled Phase 3 Study
Autor: David J. Kuter, James B. Bussel, Francis M. Senecal, Louis M. Aledort, Craig M. Kessler, Miguel A. Sanz, Howard A. Liebman, Frank T. Slovick, Reggie Kelly, Matthew Guo, Janet L. Nichol
Publikováno v: Blood. 110:565-565
AMG 531 is a novel platelet-stimulating peptibody that stimulates the thrombopoietin (TPO) receptor, and is being studied for its ability to increase production of platelets. Here we report efficacy data in nonsplenectomized patients from a randomize
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d7fa0a7a61a85dcb351dd90d7733d57
https://doi.org/10.1182/blood.v110.11.565.565
Zobrazit plný text záznamu
3
Evaluation of AMG 531 Safety in Splenectomized (S) and Nonsplenectomized (NS) Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in Two Randomized Placebo-Controlled Phase 3 Studies
Autor: Jean-François Viallard, Howard R. Terebelo, Roger M. Lyons, Reggie Kelly, Michael D. Tarantino, Matthew Guo, James N. George, François Lefrère, Alan E. Lichtin, Janet L. Nichol
Publikováno v: Blood. 110:1300-1300
AMG 531 is a novel platelet-stimulating peptibody that stimulates the thrombopoietin (TPO) receptor, and is being studied for its ability to increase production of platelets. We report safety data in both S and NS patients (pts) from 2 randomized, do
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fdd4fc6e320c23549cf7ddb9d140d1ed
https://doi.org/10.1182/blood.v110.11.1300.1300
Zobrazit plný text záznamu
4
Evaluation of AMG 531 Efficacy in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in a Randomized Placebo-Controlled Phase 3 Study
Autor: Howard A. Liebman, Janet L. Nichol, Francis M. Senecal, Reggie Kelly, Craig M. Kessler, Matthew Guo, Louis M. Aledort, Terry Gernsheimer, Frank Thomas Slovick, Vinod Pullarkat, Miguel A. Sanz
Publikováno v: Blood. 110:2-2
AMG 531 is a novel thrombopoiesis-stimulating peptibody that acts by stimulating the thrombopoietin (TPO) receptor. We report efficacy data in splenectomized patients from a randomized, double blind, placebo-controlled Phase 3 study designed to evalu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e50dfe185bb38aefc39a5fbe906de60d
https://doi.org/10.1182/blood.v110.11.2.2
Zobrazit plný text záznamu
5
Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update
Autor: Janet Nichol, Matthew Guo, Jenny Christal, Reggie Kelly, Martin Schipperus, Francois Lefrere, Mies Kappers-Klunne, Emanuelle Bourgeois, Jeffrey Wasser, Jorge Nieva, Roger Lyons, Alan Lichtin, Louis Aledort, James George, James Bussel, David Kuter
Publikováno v: Blood. 108:476-476
AMG 531 is a novel thrombopoiesis-stimulating peptibody that increases platelet production by targeting the TPO receptor. The study described here is an ongoing, open-label extension assessing the safety and efficacy of long-term, weekly, subcutaneou
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d152a97fa5315b6991bd479b964912e4
https://doi.org/10.1182/blood.v108.11.476.476
Zobrazit plný text záznamu
6
Long-Term Dosing of AMG 531 Is Effective and Well Tolerated in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura
Autor: Alan E. Lichtin, François Lefrère, Janet L. Nichol, James B. Bussel, Martin R. Schipperus, Jorge Nieva, Roger M. Lyons, David J. Kuter, James N. George, Jeffrey S. Wasser, Emanuelle Bourgeois, Jenny Christal, M. C. Kappers-Klunne, Chien-Feng Chen, Reggie Kelly, Louis M. Aledort
Publikováno v: Blood. 106:220-220
AMG 531 is a novel platelet-stimulating peptibody that targets the TPO receptor, resulting in increased production of platelets. This ongoing, open-label study assessed the safety and efficacy of long-term AMG 531 dosing in ITP patients. Eligible pat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::51c8fb09c2e236504a256fd4d1cd99f6
https://doi.org/10.1182/blood.v106.11.220.220
Zobrazit plný text záznamu
7
Safety Profile of AMG 531 in Healthy Volunteers and in Thrombocytopenic Patients with Immune Thromobocytopenic Purpura
Autor: Janet L. Nichol, Jenny Christal, Chien-Feng Chen, Reggie Kelly, Daniel E. Stepan, Elaine Sergis-Deavenport
Publikováno v: Blood. 106:1240-1240
AMG 531 is a novel platelet-stimulating peptibody that targets the thrombopoietin (TPO) receptor, resulting in an increased production of platelets. AMG 531 lacks sequence homology to native TPO. To date, AMG 531 has been administered in two phase 1
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::97bfecaf4055fb04a874c61a96dd8951
https://doi.org/10.1182/blood.v106.11.1240.1240
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje